Q32 Bio (QTTB) Gains from Investment Securities (2017 - 2026)
Q32 Bio (QTTB) recorded quarterly Gains from Investment Securities of $8584.0 in Q1 2026, down 98.2% quarter-over-quarter from $477000.0 in Q4 2025, and down 86.92% on a YoY basis from $65648.0 in Q1 2025.
Q32 Bio (QTTB) Gains from Investment Securities (2017 - 2026) Analysis & Trends
Q32 Bio's Gains from Investment Securities history runs 10 years deep, the most recent figure standing at $8584.0 for Q1 2026.
- In Q1 2026, Gains from Investment Securities fell 86.92% year-over-year to $8584.0; the TTM figure through Mar 2026 stood at $8584.0 (down 86.92% YoY), while the FY2025 annual figure was $2.2 million, changed N/A from the prior year.
- Gains from Investment Securities was $8584.0 for Q1 2026 at Q32 Bio, down from $477000.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $10.0 million in Q2 2022 to a low of -$49000.0 in Q4 2022.
- Historically, Gains from Investment Securities has averaged $1.9 million across 5 years, with a median of $623776.0 in 2023.
- The sharpest annual moves came in 2023 and 2024: Gains from Investment Securities jumped 8128.57% in 2023, then plunged 98.09% in 2024.
- A 5-year view of Gains from Investment Securities shows it stood at -$49000.0 in 2022, then surged by 8128.57% to $3.9 million in 2023, then slumped by 98.09% to $75000.0 in 2024, then jumped by 536.0% to $477000.0 in 2025, then tumbled by 98.2% to $8584.0 in 2026.
- The last three Gains from Investment Securities figures came in at $8584.0 (Q1 2026), $477000.0 (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Q32 Bio | 167.59 Mn | 116.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8,584.00 |
| Mar 31, 2026 | 8,584.00 |
| Dec 31, 2025 | 477,000.00 |
| Dec 31, 2025 | 477,000.00 |
| Sep 30, 2025 | 1.86 Mn |
| Sep 30, 2025 | 1.86 Mn |
| Jun 30, 2025 | 242,813.00 |
| Jun 30, 2025 | 242,813.00 |
| Mar 31, 2025 | 65,648.00 |
| Mar 31, 2025 | 65,648.00 |
| Dec 31, 2024 | 75,000.00 |
| Dec 31, 2024 | 75,000.00 |
| Sep 30, 2024 | 1.07 Mn |
| Sep 30, 2024 | 1.07 Mn |
| Mar 31, 2024 | 600,000.00 |
| Mar 31, 2024 | 600,000.00 |
| Dec 31, 2023 | 3.93 Mn |
| Dec 31, 2023 | 3.93 Mn |
| Sep 30, 2023 | 623,776.00 |
| Sep 30, 2023 | 623,776.00 |